Literature DB >> 20446894

Hydrops fetalis--has there been a change in diagnostic spectrum and mortality?

Christoph Czernik1, Hans Proquitté, Boris Metze, Christoph Bührer.   

Abstract

OBJECTIVE: To investigate the impact of medical progress on the diagnostic spectrum and outcome of infants with hydrops fetalis (HF). STUDY
DESIGN: We reviewed the charts of all live-born HF infants (n = 70) over a 16-year period (1993-2009). Data were compared to two published case series (Wafelman LS, Pollock BH, Kreutzer J, Richards DS, Hutchison AA. Biol Neonate 1999;75:73-81, Gainesville, Florida 1983-1992, n = 62; Simpson JH, McDevitt H, Young D, Cameron AD. Fetal Diagn Ther 2006;21:380-382, Glasgow, UK 1990-2004, n = 30).
RESULTS: Only two cases were immune HF. The proportion of infants with unexplained HF (30%), lymphatic (24%), cardiac (17%), hematological (6%) or chromosomal anomalies (6%) did not differ from the published case series. There was also no difference in overall mortality (57% vs. 55% or 67%, respectively). Low gestational age (<34 weeks), low 5-min Apgar scores (<4), and heart failure were independently associated with fatality.
CONCLUSION: The diagnostic spectrum and mortality of HF has changed little over the last 25 years. In the future, new techniques in mutational analysis will be needed to reduce the high rate of unexplained cases of HF.

Entities:  

Mesh:

Year:  2010        PMID: 20446894     DOI: 10.3109/14767058.2010.483522

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  2 in total

1.  Frequency and Prognosis of Hydrops Fetalis: A 10-Year Single-Center Experience.

Authors:  Ebru Turkoglu Unal; Ali Bulbul; Evrim Kiray Bas; Hasan Sinan Uslu
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2021-09-24

2.  Maternal mirror syndrome with foetal hydrops due to isoimunization by anti-KPa antibodies: A case report and narrative literature review.

Authors:  Juan Pina Moreno; Virginia Ortega Abad; Ana Perez Corral; Santiago Garcia-Tizon Larroca
Journal:  Clin Case Rep       Date:  2022-02-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.